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Abstract
Background: Hyperhomocysteinemia is an important and independent risk factor for vascular disease.
About 35% of patients with stroke and 47% of patients with peripheral arterial disease have elevated
plasma homocysteine (HCY) concentrations. The relationship between plasma HCY and the
methylentetrahydrofolate reductase (MTHFR) C677T polymorphism is still unclear, especially in regard to
screening/diagnostic power.
Methods:  This case-control study was performed on 96 patients, who underwent surgery due to
asymptomatic or symptomatic high grade stenosis of the internal carotid artery (ICA), and 96 healthy age
and sex-matched, controls. Plasma HCY concentration was determined using a commercial kit for fully
automated analysis (AxSYM, Abbott). The C677T polymorphism of the MTHFR-gene was assessed by
PCR.
Results: The mean plasma HCY concentration was significantly higher in the group with stenosis of ICA
compared to the controls, 12.43 ± 6.96 μM and 10.16 ± 3.16 μM, respectively, (p < 0.05). An HCY plasma
concentration of 1.5 SD above the mean value of the control group, was defined as cut-off for a
pathological versus physiological plasma concentration. The sensitivity and specificity of HCY was 0.27 and
0.94, respectively. The positive predictive value was 0.82. There was no significant difference in the
frequency of the MTHFR 677 CT and TT genotype between patients and controls (47% vs. 47% and 8.3%
vs. 11.4%, respectively). Carriers of the T-allele (CT and TT genotypes) have significantly higher plasma
HCY concentrations than CC patients, 14.1 ± 7.6 μM and 10.29 ± 5.2 μM, respectively, p < 0.05. Sensitivity
and specificity of the MTHFR C677T polymorphism (T-allele) were 0.56 and 0.40, respectively. The
positive predictive value was 0.48. There was no significant difference in plasma HCY or genotype
frequency of the MTHFR C677T polymorphism between asymptomatic and symptomatic patients.
Conclusion: Our study shows that in a population with a given pretest disease probability of 50%, the
determination of plasma HCY concentration, with a positive predictive value of 0.82, is more suitable for
screening of patients at risk than analysis of the MTHFR C677T polymorphism.
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Background
Stroke is a frequent cause of death in the developed world
with a prevalence of 1–5% in the general population. In
Germany, there are about 160,000 new cases of stroke
recorded per year, with an annual cost over 11.7 billion
dollars [1,2]. About 15% of all strokes are caused by
atherosclerotic stenosis of the carotid bulb and the ICA
[3]. Recent studies have demonstrated a reduction of
stroke by prophylactic surgical treatment of asymptomatic
high grade ICA stenosis [4] as well as by surgery for symp-
tomatic ICA stenosis in patients who have already experi-
enced a transient ischemic attack (TIA) or a stroke [5]. As
recommended by the stroke council of the American
Heart Association the best approach to reduce the burden
of stroke still remains its prevention. High-risk stroke
individuals have therefore to be identified and targetted
for specific interventions [1].
In 1969, McCully reported an autopsy case of a 7-week-
old-new-born with advanced atherosclerotic lesions and
very high plasma homocysteine concentration [6]. The
author speculated that the arterial damage was associated
with increased concentrations of HCY or a derivative of
HCY. Elevated plasma HCY concentrations are observed
in about 13% of patients with coronary artery disease,
35% of patients with stroke and up to 47% of patients
with peripheral arterial disease [7-11]. Plasma HCY con-
centration may be significantly elevated as a result of
interaction of genetic and acquired factors [12]. Two
important observations have put the research on HCY in
focus. First, hyperhomocysteinemia has been established
as an important and independent risk factor for vascular
disease. Thus, a 5 μM increase in plasma HCY concentra-
tion may be associated with a 25–30% increase in risk of
vascular events [13]. Second, an elevated HCY concentra-
tion can be normalized by vitamin substitution (folic
acid, pyridoxine hydrochloride (B6) and cyanocobalamin
(B12) with consecutive deceleration of atherosclerotic
processes [12-17].
With respect to genetic factors, homocysteinemia may be
the result of enzyme deficiency of the homocysteine inter-
mediary metabolism. Apart from rare inherited metabolic
disorders (errors in cobalamin metabolism, cystathionine
β-synthase deficiency), the most common disorder inves-
tigated has been a deficiency of methylentetrahydrofolate
reductase (MTHFR, EC 1.5.1.20). Frosst et al. [18] identi-
fied a C-to-T substitution at nucleotide 677 that converts
alanine to valine (MTHFR C677T polymorphism). The
mutation of the heterozygous or homozygous form corre-
lated with reduced enzyme activity and increased thermo-
lability in lymphocyte extracts [18,19]. This is the most
common mutation and has a prevalence in the general
population, 5–10% as TT and up to 40% as CT genotype
[20,21]. Nevertheless, due to the high incidence in the
general population and its physiological role, the 677C-T
mutation may represent an important genetic risk factor
of homocysteine associated vascular disease [18,20,21].
Kang et al. suggested that thermolabile MTHFR was asso-
ciated with the development of coronary artery disease
[22]. A generally accepted hypothesis is that homozygous
TT-genotype leads to the hyperhomocystinemia with a
consecutive premature vascular disease. On the other side,
heterozygous carriers have mild hyperhomocysteinemia
with a predisposition for accelerated atherosclerosis
[19,20,22]. Although determination of different polymor-
phisms became a standard diagnostic tool, the relation-
ship between MTHFR C677T polymorphism, related
clinical entities and plasma homocysteine concentration
is still not fully understood [23-25].
We performed a case-control study in the patients who
were admitted for surgical treatment of high grade ICA ste-
nosis to assess the screening and/or diagnostic power of
the MTHFR C677T polymorphism against plasma homo-
cysteine concentration. This study was conducted in order
to improve our knowledge on the role of the MTHFR
C677T polymorphism and plasma HCY in patients with
ICA stenosis, to rationalize the diagnostic work-up and to
subsequently reduce unnecessary costs in routine diag-
nostics.
Methods
The patient group consisted of 96 persons (age range 40–
87 years) who were admitted to our hospital for surgery
due to a high-grade carotid artery stenosis (at least 80%).
Thirty-four patients were asymptomatic and 62 sympto-
matic and had already experienced TIA or stroke. The diag-
nosis of ICA stenosis was confirmed by doppler and
duplex sonography in all patients and, additionally, by
digital subtraction angiography (DAS) or magnetic reso-
nance angiography (MRA) in some cases. All patients had
a cranial computed tomography (CT) or magnetic reso-
nance imaging (MRI) performed to evaluate preoperative
brain damage. Ninety-six healthy volunteers (age range
45–83 years) without evidence of atherosclerosis or deep
vein thrombosis represented the control group. The sex
distribution was uniform in both groups, 23% (n = 22)
women and 77% (n = 74) men, respectively.
A careful anamnestic evaluation and physical examina-
tion were performed in all participants including evalua-
tion of nutrition. Patients with vitamin and mineral
supplementation and subjects with known disorders of
B6, B12 and folate metabolism, as well as patients suffer-
ing from hematological and oncological disorders were
excluded. Furthermore, subjects under continuous or
recent medication, which are known to influence HCY,
folic acid and vitamins B metabolism, women with hor-
mone contraception or any other form of hormone sub-Thrombosis Journal 2006, 4:16 http://www.thrombosisjournal.com/content/4/1/16
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stitution were also excluded. This study was performed
according to the Helsinki declaration and was approved
by the local ethical committee. A written consent has been
obtained from each participant.
Biological sample collection
Venous blood was obtained by puncture of the cubital
vein, collected in EDTA tubes and immediately centri-
fuged at 2500 rpm for 10 min at 4°C. Cells were further
assessed for genetic polymorphism. The plasma fraction
was aliquoted for biochemical analysis. One aliquot was
stored at -40°C to await analysis of homocysteine, folic
acid or B12.
Homocysteine assay
Homocysteine plasma concentration was measured using
a standard commercial diagnostic kit (AxSYM Homo-
cystein) for the fully automated Abbott AxSYM system
(Abbott Diagnostic Division, Wiesbaden, Germany).
Briefly, the assay included 3 analytical steps: 1) reduction
of protein-bound homocysteine and other homocysteine
fractions to free homocysteine using dithiothreitol, 2)
enzymatic conversion using synthetic activity of S-aden-
sylhomocysteine (SAH)-hydrolase in excess of adenosine,
3) a fluorescence polarisation immunoassay (mouse anti-
SAH antibody) for determination of S-adenosylhomo-
cysteine. Linearity of homocysteine determinations in the
water and human whole plasma were proven using serial
dilutions of HCY standards (range 0.6–600 μM). Intra-
and inter-assay variations and possible effects of freezing
and thawing were also assessed. According to the results
published by others and following the manufacturer's rec-
ommendations, the cut-off value for an elevated HCY
concentration was set at 1.5 SD above the mean value of
the control group.
Determination of plasma folic acid and B12 concentration
Folic acid and vitamine B12 plasma concentrations were
assessed in one aliquot of stored plasma using standard
commercial Abbott kits, the AxSYM Folate Assay and the
AxSYM B12 Assay. AxSYM Folate assay is a Ion-Capture-
Assay for quantitative determination of folic acid in
human sera or plasma and AxSYM B12 is a microparticle
enzyme intrinsic factor assay (MEIA) for quantitative
determination of vitamin B12 in human serum or plasma.
Both assays were conducted according to the manufac-
turer's instruction using AxSYM analyzer.
MTHFR C677T polymorphism
The MTHFR C677T polymorphism was assessed using the
Lightcycler-MTHFR C677T mutation detection protocol,
previously described in detail [26]. Briefly, the mutation
detection protocol was adapted for high-speed PCR in
glass capillaries using the Lightcycler Instrument (Light-
Cycler® Roche Diagnostics GmbH, Mannheim, Germany)
and hybridisation probes for genotyping of the C677T
point mutation in exon 4 of the MTHFR gene in human
DNA. A 233 bp fragment of the MTHFR gene is amplified
from genomic DNA using specific primers and the PCR
product is detected by fluorescence (Lightcycler -Red 640)
using a specific pair of hybridisation probes.
Statistics
The data are presented as means ± SD. Statistical signifi-
cance of the results was analysed using the Student's t-test.
In cases where the data distribution was not compatible
with the application of Student's t-test, Wilcoxon's test of
the sum of ranks was applied. Regression analysis was
based on individual measurements using the Spearman's
rank correlation coefficient. In addition, non-linear
regression analysis was compared with the rank correla-
tion analysis. Statistical analyses were performed using
SPSS for Windows, version 6.0.1. A P-value below 0.05
(two-tailed) was assumed to indicate a significant differ-
ence.
Within both, the patient and the control group, interindi-
vidual differences of the plasma HCY concentration were
expressed as the coefficient of variation (CVobs). To
obtain the real biological variability of homocysteine
plasma concentration, the observed variability was cor-
rected for methodological variability, which was assessed
separately using plasma sample standards with known
concentrations of homocysteine and expressed as the
coefficient of variation of the method (CVmeth). A real
biological coefficient of variation was calculated as CVbiol
= (CVobs2-CVmeth2)1/2. For evaluation of the HCY
plasma concentration and MTHFR C677T polymorphism,
as a marker of enhanced risk of ICA stenosis, Bayes theo-
rem was used [27].
Results
Linearity of HCY plasma determination in human plasma
was tested by adding aliquots of known HCY standards to
plasma and processing the samples as described above.
The average recovery was 104% and 107% in water and
plasma dilutions, respectively. Correlation between
diluted HCY standards in water and human plasma HCY
measurements was 0.94. Temperature changes (freezing,
thawing), which may affect homocysteine distribution
among protein-bound, free and mixed disulphides had
no influence on the accuracy of the assay. Intra- and inter-
assay variations as well as the coefficients of variation with
and without freezing, were identical, yielding a coefficient
of variation of the method (CVmeth) of 0.05. Descriptive
statistical data for total plasma HCY and MTHFR C677T
polymorphism are summarized in the Table 1. There was
a significant difference between the control and patient
group regarding total plasma HCY (p < 0.05). The plasma
HCY in the patients averaged 12.43 ± 6.96 μM (range 3.4Thrombosis Journal 2006, 4:16 http://www.thrombosisjournal.com/content/4/1/16
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to 40.8 μM) and showed significantly higher biological
coefficient of variation (CV) related to the control, 0.47 vs.
0.30 respectively, p < 0.05. Although the average B12 and
folate plasma concentration did not differ significantly
between both groups (p > 0.05), a biological coefficient of
variation of B12 and folate was 2.4- and 2.7-fold higher in
the patients compared to the controls.
In the control group, male subjects showed higher total
plasma HCY concentrations than female subjects (10.8 ±
3.35 μM vs. 9.30 ± 2.03 μM p < 0.05). This gender-related
significant difference in the total plasma HCY concentra-
tion was not observed in the group with stenosis of ICA.
Male patients had no significantly different plasma HCY
as compared to females (12.72 ± 7.39 μM vs. 11.45 ± 5.27
μM, p > 0.05). In the control group, HCY correlated signif-
icantly with age (r = 0.30, p < 0.05), while in the patient
group no such a relationship with age was observed (r =
0.18, p > 0.05). However, in the control and the patient
groups no significant correlation was found between the
HCY concentration and age, when related to gender (p =
0.34 and p = 0.63, respectively). An interesting observa-
tion was found in regard to plasma HCY and folate con-
centration. In both groups, a significant inverse relation
between folate and plasma HCY was observed (r = -0.32
and r = -0.22, p < 0.05, respectively). Between patients
with low and high folate concentrations (defined as < of
40 % and % > 140% of the mean plasma folate concentra-
tion), a statistical difference in the plasma HCY concentra-
tion was observed, 14.04 ± 6.41 vs. 10.15 ± 4.21 μM, p <
0.01, respectively. HCY in both examined groups did not
show significant correlation with plasma B12 concentra-
tion, r = 0.01.
The frequency distributions of the MTHFR C677T poly-
morphism are summarized in Table 1. The MTHFR CC
genotype was present in 44% of patients and 40% of con-
trols. Heterozygosity for MTHFR (CT genotype) was
present in a similar frequency in both groups (48% vs.
47%, p > 0.05). MTHFR TT genotype was confirmed in
eleven control subjects and in eight patients. The fre-
quency of the TT genotype was slightly higher in the con-
trol group but the difference was not statistically
significant, 11.4% and 8.3%, respectively, p > 0.05. There
was no significant difference in the frequency of the
MTHFR 677T polymorphism related to the gender, nei-
ther in control subjects nor in patients with ICA stenosis.
The relation between MTHFR C677T polymorphism and
plasma HCY as well as plasma B12 and folate concentra-
tion in the patient group is presented in the Table 2.
Patients carrying the T-allele (CT and TT genotype) had
significantly higher plasma HCY concentrations than CC
patients, 14.1 ± 7.6 μM vs. 10.29 ± 5.2 μM, respectively, p
< 0.05. Interestingly, there was no statistically significant
difference between folate and B12 concentration in regard
to the MTHFR C677T polymorphism, p > 0.05. The coef-
ficient of correlation between HCY and folate as well as
HCY and B12, in regard to the MTHFR 677T polymor-
phism, was not statistically significant; between HCY and
folate in the patients, carriers of T-allele was r = -0.24 and
in the CC-patients r = -0.14, p > 0.05. The highest coeffi-
cient of correlation was observed between HCY and folate
concentration at CT-patients, r = -0.28, p = 0.06.
For further evaluation, the patient population was strati-
fied according to the clinical severity of ICA stenosis (TIA
or stroke). Compared to asymptomatic patients, sympto-
matic patients had higher HCY plasma concentrations,
but the difference was not statistically significant (12.83 ±
6 μM and 11.54 ± 8 μM, respectively, p > 0.05). The fre-
quency of MTHFR 677 CT or TT genotypes did not differ
between asymptomatic and symptomatic patients (38%
and 53%, 8.8% and 8%, respectively, p > 0.05).
To evaluate the total plasma HCY concentration and the
MTHR polymorphism as a marker of ICA stenosis, Bayes
theorem was used [16]. The cut-off value for pathological
plasma HCY concentration was set to the mean + 1.5 SD
of the plasma HCY concentration, measured in the con-
trol group, equivalent to 14.9 μM. Using this cut-off value,
27% of the patients with ICA stenosis had increased total
plasma HCY concentration compared to the remaining
Table 2: Descriptive statistical data related to the MTHFR 
C677T polymorphism and plasma HCY concentration in 
patients with stenosis of ICA.
ICA stenosis
CC-HCY, μM 10.29 ± 5.25
CT-HCY, μM 14.32 ± 7.66
TT-HCY, μM 12.81 ± 8.17
CC-B12, pg/mL 381 ± 210
CT-B12, pg/mL 376 ± 185
TT-B12, pg/mL 412 ± 85
CC-Folate, mg/mL 7.82 ± 4.10
CT-Folate, mg/mL 6.15 ± 3.08
TT-Folate, mg/mL 7.91 ± 2.21
Table 1: Age, biochemical data and MTHR C677T polymorphism 
in the controls and patients with ICA stenosis
Parameter Control ICA p
Age, years 66.8 ± 9.9 68.9 ± 8.9 >0.05
Total homocysteine, μM 10.16 ± 3.16 12.43 ± 6.96 <0.001
B12, pg/ml 324 ± 67 376 ± 188 >0.05
Folate, ng/ml 6.73 ± 1.28 6.62 ± 3.52 >0.05
MTHFR CC, % 40 44 >0.05
MTHFR CT, % 48 47 >0.05
MTHFR TT, % 11.4 8.3 >0.05Thrombosis Journal 2006, 4:16 http://www.thrombosisjournal.com/content/4/1/16
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patients, 21.70 ± 6.9 and 9.17 ± 2.82 μM, respectively, p <
0.001. Both sensitivity and specificity of plasma HCY con-
centration for the risk of ICA were 27% and 94%, respec-
tively (Table 3.). When the cut-off value was set to the
mean plasma HCY concentration + 1SD, sensitivity was
slightly enhanced and specificity was slightly reduced. In
our study population with a given pre-test disease proba-
bility of 50%, the positive predictive value of total plasma
HCY concentration was 0.82, according to the Bayes the-
orem. At the same time, sensitivity and specificity of the
MTHFR polymorphism (both CT and TT genotypes) was
0.56 and 0.40, respectively. The positive predictive value
was 0.48. Considering a prevalence of ICA stenosis in the
general population of approximately 3% [15], the calcu-
lated positive predictive value for HCY and MTHFR (CT
and TT genotype) was 0.12. and 0.02, P < 0.01, respec-
tively.
According to the discrepancy between recruited subjects
in regard to gender distribution (23% females and 77%
males represent the gender structure of 96 consecutive
patients admitted to our clinic with related symptoms) a
separate statistical analysis was performed.
The analysis revealed that homocysteine plasma concen-
trations between male patients and male controls showed
a significant statistical difference, 12.72 ± 7.34 μM and
10.8 ± 3.35 μM, p < 0.05, respectively. The sensitivity and
specificity in the male subgroup compared to the whole
collective were 0.26 and 0.27, 0.96 and 0.94, respectively.
A positive predictive value, calculated in the male sub-
group, was 0.86 compared to the 0.82 in the all subjects.
Similarly, a separate analysis of the MTHFR 677T poly-
morphism in the male subgroup did not influence the
results. Sensitivity and specificity were 0.54 and 0.38 and
did not differ significantly compared to the whole group
(0.56 and 0.40, respectively). The positive predictive value
was 0.46 (0.48 in the whole group).
Discussion
In this study we explored the association between the
MTHFR C677T polymorphism and plasma HCY concen-
tration in patients with ICA stenosis. The main aim was to
evaluate the relevance of this genetic marker in compari-
son to plasma HCY and to assess the screening and/or
diagnostic power of the MTHFR C677T polymorphism
against plasma homocysteine concentration.
The study provided the following major results:
1. Homocysteine plasma concentration was significantly
higher in the patient group compared to the control.
2. The genotype frequency of the MTHFR C677T polymor-
phism revealed no difference between the patient group
and the group of healthy individuals.
3. Patients, carrying the T-allele had significantly higher
plasma HCY concentrations than CC patients.
4. There was no statistically significant difference between
symptomatic and asymptomatic patients in regard to
plasma HCY concentration and genotype frequency of the
MTHFR C677T polymorphism.
5. The determination of plasma HCY concentration with
a positive predictive value of 0.82 was more suitable for
screening and monitoring of patients at risk than analysis
of the MTHFR C677T polymorphism (positive predictive
value 0.48).
In order to evaluate total plasma HCY and MTHFR C677T
polymorphism as marker of ICA stenosis, this study
(index test) was performed according to "gold standard"
procedures [27]. This requires that the status of patients is
precisely defined (definitive procedure) and that pre-test
probability of the disease is known. It is important to real-
ize the homogeneity of the groups in respect to the selec-
tion parameters. Under these conditions, the calculated
statistics show that assessment of plasma HCY is superior
compared to MTHFR genotyping (Table 3). The positive
predictive value, which is defined as probability of dis-
ease, if the test result is positive, has been calculated
according to the Bayes theorem. The Bayes theorem com-
bines three factors – sensitivity, specificity and disease
prevalence, in the examined population. To calculate the
prevalence, that is incidence of the disease in the exam-
ined population, is the most critical. In our model popu-
lation, the prevalence was precisely defined by selecting
96 patients with diagnosed ICA stenosis and 96 healthy
Table 3: Sensitivity, specificity and positive predictive value of HCY plasma determinationand MTHFR C677T-polymorphism in 
patients with ICA stenosis.
Sensitivity Specificity Positive predictive value
HCY (cut-off 14.90 μM)* 0.27 0.94 0.82
MTHFR (CT and TT) 0.56 0.40 0.48
*Cut-off value = 1.5 SD above the mean value of the control groupThrombosis Journal 2006, 4:16 http://www.thrombosisjournal.com/content/4/1/16
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individuals as controls. Table 3 shows a positive predic-
tive value for HCY of 0.82 in regard to the incidence of 50
%. Taking into consideration that age and gender distribu-
tion as well as environmental and behavioural factors
were similar in both groups, a sensitivity of 0.27 with a
specificity of 0.94 indicated that an altered HCY metabo-
lism could be involved in about one third of all cases of
ICA stenosis, with a total probability of 94%. If the find-
ings on the model population are transferred to the gen-
eral population, the much lower incidence of ICA
stenosis, namely approximately 3%, has to be considered
[1]. Since approximately 27% of subjects with ICA steno-
sis had elevated HCY and 94 % of healthy controls had a
normal total plasma HCY concentration, the positive pre-
dictive value is 0.12 for the general population. From
these results we concluded that measurement of total
plasma HCY concentration should not serve as a screen-
ing test for ICA stenosis in the general population but
rather as a screening test and/or monitoring marker in cer-
tain high-risk groups (e.g. individuals with higher familiar
incidence of ICA stenosis or other forms of peripheral
arterial obstructive disease).
As it is evident from Table 1, the total plasma HCY was sig-
nificantly higher in the patient group compared to con-
trols. As cut-off value was set 1.5 SD above the mean value
of the control group, HCY plasma concentration was
increased in 27% patients and ranged between 3.8 and 40
μM. In addition to the difference in the mean HCY con-
centration, the coefficient of variation (CVobsv) of
plasma HCY differed significantly between patients and
controls (0.47 and 0.30, respectively, p < 0.05). Taking
into consideration that the method used for plasma HCY
measurement exhibited variation (CVmeth) of 0.05, the
largest fraction of the noted coefficient of variation could
be attributed to true biological variation. A possible expla-
nation for the higher plasma HCY and the higher CV of
plasma HCY in the patients could not be be given through
the difference in the genotype frequency of MTHFR 677T
polymorphism. Namely, the genotype frequency of the
MTHFR 677T polymorphism revealed no difference
between patients and healthy individuals.
However, higher plasma HCY concentration and CV of
plasma HCY in the group of patients could not be
explained by the MTHFR C677T polymorphism. A careful
data evaluation showed that there was no consistent rela-
tionship between genotype frequency, vitamin status and
plasma HCY. An inconsistent relation between examined
determinants might be explained by the presence of some
other unidentified genetic linkage or unknown risk fac-
tors, which could have an impact on the development of
hyperhomocysteinemia.
One possibility is that other mutations affect the MTHFR
gene and have influence on the plasma HCY concentra-
tion. Van der Put et al. [28] for first the time reported the
presence of an A1298C mutation of the MTHFR gene.
Although three common MTHFR polymorphisms
(C677T, C1298A, C1711T) have already been reported
[29], only one polymorphism (C677T) has been investi-
gated intensively as a risk factor for occlusive arterial vas-
cular disease. The MTHFR A1298C polymorphism causes
a glycine to alanine substitution in the MTHFR protein
and has an allele frequency similar to that of MTHFR
C677T [28-30]. The significance of this polymorphisms
requires, however, further investigation.
Nevertheless, the application of Bayes theorem in our
study design indicated that determination of MTHFR
677T polymorphism as screening or diagnostic tool is of
minor importance.
Conclusion
Our study showed that in a population with a given pre-
test disease probability of 50%, the determination of
plasma HCY concentration, with a positive predictive
value of 0.82, is more suitable for screening and monitor-
ing of patients at risk than an analysis of the MTHFR
C677T polymorphism.
From our results we concluded that the measurement of
the total plasma HCY concentration does not serve as a
screening test for ICA stenosis in the general population
but rather as a screening test and/or monitoring marker in
certain risk groups (e.g. individuals with higher familiar
incidence of ICA stenosis or other forms of peripheral
arterial obstructive disease).
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